{"organizations": [], "uuid": "428e5d5564a365da7de720f0684b60429006710f", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180214.html", "section_title": "Archive News &amp; Video for Wednesday, 14 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-sensorion-announces-positive-sens/brief-sensorion-announces-positive-sens-401-phase-1-clinical-trial-results-idUSFWN1Q403T", "country": "US", "domain_rank": 408, "title": "BRIEF-Sensorion Announces Positive SENS-401 Phase 1 Clinical Trial Results", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.966, "site_type": "news", "published": "2018-02-14T14:21:00.000+02:00", "replies_count": 0, "uuid": "428e5d5564a365da7de720f0684b60429006710f"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-sensorion-announces-positive-sens/brief-sensorion-announces-positive-sens-401-phase-1-clinical-trial-results-idUSFWN1Q403T", "ord_in_thread": 0, "title": "BRIEF-Sensorion Announces Positive SENS-401 Phase 1 Clinical Trial Results", "locations": [], "entities": {"persons": [{"name": "sensorion", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 14 (Reuters) - SENSORION SA:\n* ANNOUNCES NEW RESEARCH DATA‍​ * SENS-401 RESULTS SUGGEST DAILY DURATION OF DRUG EXPOSURE IS MORE IMPORTANT THAN MAXIMAL DOSE EXPOSURE\n* 28-DAY SENS-401 TREATMENT PROVIDES BETTER HEARING OUTCOME THAN A 14-DAY TREATMENT\n* PHASE 1 CLINICAL TRIAL SHOWS SENS-401 IS WELL TOLERATED\n* TRIAL SHOWS SENS-401 PHARMACOKINETIC PROFILE CONFORMS TO EXPOSURES NEEDED FOR PRECLINICAL EFFICACY\n* INTENDS TO START PHASE 2 STUDY WITH SENS-401 IN THIS INDICATION DURING H1 2018‍​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-14T14:21:00.000+02:00", "crawled": "2018-02-15T20:51:33.000+02:00", "highlightTitle": ""}